Psoriatic Arthritis Market to Grow Positively at a Paltry CAGR During the Study Period, DelveInsight, UCB Biopharma, Sun Pharmaceutical, BMS, Affibody AB, Janssen Biotech, Amgen, Eli Lilly and Company, AbbVie, Pfizer

DelveInsight's "Psoriatic Arthritis - Market Insight, Epidemiology and Market Forecast - 2032" report provides current treatment practices, emerging drugs, Psoriatic Arthritis market share of the individual therapies, current and forecasted Psoriatic Arthritis market size from 2019 to 2032 segmented by seven major markets. The report also offers current Psoriatic Arthritis therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Psoriatic Arthritis market.
Psoriatic Arthritis Overview
Psoriatic arthritis (PsA) is a type of arthritis linked to psoriasis, a chronic skin and nail condition marked by red, scaly patches and thick, pitted fingernails. Symptoms of PsA, like those of rheumatoid arthritis (RA), include joint inflammation. However, PsA typically involves fewer joints and does not produce the characteristic antibodies associated with RA.

PsA shares clinical similarities with other inflammatory arthritic conditions such as RA, reactive arthritis (ReA), and ankylosing spondylitis (AS). Diagnosis can sometimes be challenging. Unlike PsA, RA is usually symmetrical and tends to spare the distal interphalangeal (DIP) joints. AS typically has an earlier onset and is characterized by symmetric sacroiliac involvement, as opposed to the asymmetric pattern seen in PsA.

The severity of PsA can vary, but treatment is essential regardless of the degree. Untreated PsA can lead to permanent joint damage and disability. Treatment aims to prevent irreversible joint damage and reduce inflammation that may contribute to other health issues. While there is no cure for PsA, treatment objectives include slowing disease progression, enhancing quality of life (QoL), alleviating pain, and maintaining joint mobility. For most PsA patients, pharmacological treatment begins with a trial-and-error approach, starting with corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) for symptom management. If these are insufficient, physicians may prescribe conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and, if necessary, biological DMARDs.
Request for sample report @ https://www.delveinsight.com/report-store/psoriatic-arthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Psoriatic Arthritis Epidemiological Insights
The total Psoriatic Arthritis Prevalent Patient Population in the 7MM countries was close to 1.5 million in 2021.
As per the estimates, the US had the highest total prevalent patient population of psoriatic arthritis (PsA) population in 2021. Among the EU5 countries, Spain had the highest total prevalent patient population of psoriatic arthritis (PsA), with more than 200,000 cases, followed by Italy in 2021. On the other hand, France had the lowest total prevalent patient population of psoriatic arthritis (PsA), close to 53,000 cases in 2021.
Key highlights from the Psoriatic Arthritis Market Report:
In 7MM, the Psoriatic arthritis Market Size was approximately USD 9 billion in 2021.
The leading companies working in the Psoriatic Arthritis Market include bimekizumab (UCB Biopharma), tildrakizumab (Sun Pharmaceutical), deucravacitinib (BMS), and izokibep (Affibody AB)., and others.
Psoriatic Arthritis Treatment Market
Several companies are actively developing new therapies for Psoriatic Arthritis, including bimekizumab (UCB Biopharma), tildrakizumab (Sun Pharmaceutical), deucravacitinib (BMS), and izokibep (Affibody AB).

Bimekizumab, developed by UCB Biopharma, is an investigational humanized monoclonal IgG1 antibody that targets and inhibits IL-17A and IL-17F-two crucial cytokines involved in inflammatory processes. While IL-17A and IL-17F share some biological functions, IL-17F can drive inflammation independently of IL-17A.

Bimekizumab's safety and efficacy are under evaluation through a comprehensive clinical program, including several Phase III trials specifically for Psoriatic Arthritis.

Tildrakizumab, from Sun Pharmaceutical, is a humanized IgG1/k monoclonal antibody that binds selectively to the p19 subunit of IL-23. This binding inhibits IL-23's interaction with its receptor, thereby reducing the release of pro-inflammatory cytokines and chemokines. In the U.S., ILUMYA (tildrakizumab) is approved for treating adults with moderate-to-severe plaque psoriasis who need systemic therapy or phototherapy.

Currently, tildrakizumab is being tested in Phase III clinical trials for Psoriatic Arthritis in patients who have previously been treated with anti-TNF agents, as well as those who are anti-TNF naïve. The company has also submitted a marketing application for tildrakizumab's approval for moderate-to-severe psoriasis and Psoriatic Arthritis in Japan.
Promising Therapies in the Psoriatic Arthritis Pipeline
Bimekizumab
Tildrakizumab
Deucravacitinib
Izokibep
And others
Discover more about Psoriatic Arthritis therapies in the pipeline @ https://www.delveinsight.com/sample-request/psoriatic-arthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Leading Companies Working in the Psoriatic Arthritis Market
UCB Biopharma
Sun Pharmaceutical
BMS
Affibody AB
And others
To understand key companies related to the Psoriatic Arthritis Market, get a snapshot of the Psoriatic Arthritis Regulatory and Patent Analysis @ https://www.delveinsight.com/sample-request/psoriatic-arthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Psoriatic Arthritis Market Report
Study Period: 2019-2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Psoriatic Arthritis Companies: UCB Biopharma, Sun Pharmaceutical, BMS, Affibody AB, and others
Key Psoriatic Arthritis Pipeline Therapies: Bimekizumab, Tildrakizumab, Deucravacitinib, Izokibep, and others
Therapeutic Assessment: Psoriatic Arthritis current marketed and emerging therapies
Psoriatic Arthritis Market Dynamics: Psoriatic Arthritis market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Psoriatic Arthritis Market Access and Reimbursement
Table of Contents
1. Psoriatic Arthritis Market Key Insights
2. Psoriatic Arthritis Market Report Introduction
3. Psoriatic Arthritis Market Overview at a Glance
4. Psoriatic Arthritis Market Executive Summary
5. Disease Background and Overview
6. Psoriatic Arthritis Treatment and Management
7. Psoriatic Arthritis Epidemiology and Patient Population
8. Patient Journey
9. Psoriatic Arthritis Emerging Drugs
10. 7MM Psoriatic Arthritis Market Analysis
11. Psoriatic Arthritis Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Psoriatic Arthritis Market Drivers
15. Psoriatic Arthritis Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Download our report @ https://www.delveinsight.com/sample-request/psoriatic-arthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Trending Reports By DelveInsight:

Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market

Lebers Hereditary Optic Neuropathy Lhon Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market

Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market

Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market

Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market

Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market

Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market

Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market

Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market

Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market

Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market

Hypoplastic Left Heart Syndrome Hlhs Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market

Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market

Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market

Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market

Clinically Isolated Syndrome CIS Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market

Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market

Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market

Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market

Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market

Contact Us:

Kritika Rehani
info@delveinsight.com
+14699457679

About DelveInsight:

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.